Nasdaq:ALXO
ALX ONCOLOGY HOLDINGS INC
A pre-commercial oncology company advancing an immunotherapy portfolio funded primarily by common share issuances to support high R&D expenditures.
Key Metrics
Investment Thesis
Bull Case
Investors may view ALXO as a high-risk, high-reward opportunity given its focus on promising immunotherapy assets with no current debt obligations beyond manageable long-term liabilities. The company's substantial equity base and recent financing activities suggest management is actively securing capital to advance the pipeline toward potential commercialization milestones.
Bear Case
The stock faces severe challenges due to six consecutive years of profitability, with 2024 losses worsening to $134.8M amid rising R&D costs that consumed over $142M in operating expenses. Without a clear path to commercial revenue or successful regulatory approvals, the company risks complete capital erosion through continuous dilution and burning through its $17.6M cash reserves.
About ALX ONCOLOGY HOLDINGS INC
ALXO (ALX ONCOLOGY HOLDINGS INC) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy solutions for oncology. The company serves the global market with a pipeline targeting various cancer indications, currently operating without commercial revenue while funding operations through equity financing.
Analysis
Management Discussion
Management has successfully maintained a strong cash position despite reporting a net loss of $134.8M, primarily driven by substantial research and development expenditures of $116.4M. The company relies on equity financing, evidenced by $29.7M in share issuances and $30.8M from financing activities, to offset the significant operating cash outflow of $121.9M.
Industry Overview
The oncology sector is characterized by high failure rates in clinical trials but offers substantial rewards for drugs that achieve market approval, with immunotherapy representing a rapidly growing therapeutic modality. Companies in this space typically require billions in funding before generating revenue, making the current lack of income for ALXO standard for pre-commercial entities.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $127.4M | $170.3M | $142.5M |
| Operating Income | $-127.4M | $-170.3M | $-142.5M |
| R&D | $98.4M | $141.8M | $116.4M |
| G&A | $29.0M | $28.5M | $26.1M |
| Stock-Based Comp | $23.8M | $26.3M | $27.1M |
| D&A | $342.0K | $836.0K | $872.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $4.0M | $9.5M | $7.6M |
| Interest Expense | — | $1.6M | $1.7M |
| Interest Income | — | $10.6M | $9.4M |
| Pre-Tax Income | $-123.4M | $-160.8M | $-134.8M |
| Income Tax | $64.0K | $0 | $0 |
| Continuing Ops | $-123.5M | $-160.8M | $-134.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-123.5M | $-160.8M | $-134.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-123.5M | $-160.8M | $-134.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $271.0M | $188.7M | $134.4M |
| Cash & Equivalents | $48.8M | $22.4M | $17.6M |
| Marketable Securities | $217.4M | $160.3M | $110.2M |
| Prepaid Expenses | $4.8M | $5.9M | $6.6M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $35.5M | $53.9M | $13.4M |
| PP&E (Net) | $3.9M | $3.6M | $2.9M |
| Operating Leases | $5.6M | $4.8M | $4.0M |
| LT Investments | $16.7M | $35.4M | $3.5M |
| Other LT Assets | $9.3M | $10.0M | $3.0M |
| Total Assets | $306.5M | $242.6M | $147.8M |
| Current Liabilities | $28.3M | $36.0M | $18.5M |
| Accounts Payable | $8.1M | $8.6M | $4.5M |
| Current Debt | $0 | $0 | $435.0K |
| Current Leases | $755.0K | $847.0K | $949.0K |
| Other Current Liab | $19.5M | $26.6M | $12.6M |
| Long-Term Liabilities | $14.7M | $16.8M | $15.7M |
| Long-Term Debt | $9.4M | $9.6M | $9.5M |
| LT Operating Leases | $5.3M | $4.4M | $3.5M |
| Other LT Liab | $53.0K | $2.8M | $2.7M |
| Total Liabilities | $43.0M | $52.8M | $34.2M |
| Shareholders' Equity | $263.5M | $189.7M | $113.6M |
| Retained Earnings | $-325.5M | $-486.3M | $-621.1M |
| AOCI | $-845.0K | $256.0K | $275.0K |
| Total L&E | $306.5M | $242.6M | $147.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-123.5M | $-160.8M | $-134.8M |
| Non-Cash Adjustments | $23.0M | $21.2M | $38.3M |
| Working Capital Changes | $11.3M | $9.3M | $-25.4M |
| Cash from Operations | $-89.2M | $-130.4M | $-121.9M |
| Capital Expenditures | $1.4M | $1.3M | $447.0K |
| Cash from Investing | $-235.4M | $44.7M | $86.3M |
| Cash from Financing | $9.9M | $59.3M | $30.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-314.8M | $-26.4M | $-4.8M |
| Beginning Cash | $363.7M | $48.9M | $22.5M |
| Ending Cash | $48.9M | $22.5M | $17.6M |
Frequently Asked Questions
How does ALX ONCOLOGY HOLDINGS INC make money?
The company's financials indicate a single-stage clinical development model with no current commercial revenue streams, where all reported cash flows are driven by financing activities and non-cash adjustments related to equity issuance and R&D spend rather than product sales or licensing fees.
What are the main risks for ALXO?
1. Total lack of commercial revenue leading to continuous net losses exceeding $134M annually; 2. Heavy dependence on successful completion of clinical trials to secure future financing; 3. Dilution risk from frequent common share issuances averaging nearly $30M per year; 4. Operational burn rate consuming majority of operating expenses and R&D costs without product generation.
What is ALXO's competitive advantage?
1. Novel immunotherapy platform targeting unmet oncology needs; 2. Significant liquidity position of $17.6M in cash providing runway for clinical trials; 3. Minimal debt burden with only $9.5M in long-term obligations compared to substantial equity capitalization.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.